5-[(E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[(E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one
• 化学式: C₂₁H₂₇F₂N₅O₂
• 分子量: 419.5
• InChiKey: WPTLQOYLIXWRNN-SZKZHMJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  95
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• IMPROVED METHODS FOR TREATING ISCHEMIA
  申请人：Fate Therapeutics, Inc.

  公开号：EP3381456A1

  公开（公告）日：2018-10-03

  The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.

  本发明提供了包含干细胞和/或祖细胞的组合物，这些干细胞和/或祖细胞经过处理，增强了治疗缺血的治疗特性。特别是，本发明涉及使用具有增强治疗特性的干细胞和/或祖细胞治疗缺血组织、因缺血而受损的组织或至少一种与缺血组织或因缺血而受损的组织相关的症状。
• CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
  申请人：Fate Therapeutics, Inc.

  公开号：EP3770252A1

  公开（公告）日：2021-01-27

  The present invention is directed to a population of modified hematopoietic stem cells (HSCs), comprising an exogenous copy of a polynucleotide encoding PD-L1. The present invention also relates to pharmaceutical compositions comprising the modified HSCs and to their use in methods of treating immunological disorders.

  本发明涉及一种修饰的造血干细胞（HSCs）群体，其中包含一个编码PD-L1的多核苷酸的外源拷贝。本发明还涉及包含经修饰造血干细胞的药物组合物及其在治疗免疫性疾病方法中的用途。
• Methods of treating ischemia
  申请人：FATE THERAPEUTICS, INC.

  公开号：US10111907B2

  公开（公告）日：2018-10-30

  The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.

  本发明提供了包含干细胞和/或祖细胞的组合物，这些干细胞和/或祖细胞经过处理，增强了治疗缺血的治疗特性。特别是，本发明涉及使用具有增强治疗特性的干细胞和/或祖细胞治疗缺血组织、因缺血而受损的组织或至少一种与缺血组织或因缺血而受损的组织相关的症状。
• Enhanced stem cell composition
  申请人：Fate Therapeutics, Inc.

  公开号：US10172888B2

  公开（公告）日：2019-01-08

  The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

  本发明提供了细胞治疗的改进方法。特别是，本发明提供了具有改善的移植和归巢特性的增强型造血干细胞和祖细胞的治疗组合物，以及制造治疗组合物的方法。本发明进一步提供了提高造血干细胞和祖细胞移植疗效的方法，包括将治疗组合物移植给需要造血系统重建的受试者。
• Cell potency assay for therapeutic potential
  申请人：FATE THERAPEUTICS, INC.

  公开号：US10851412B2

  公开（公告）日：2020-12-01

  The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo.

  本发明提供了用于测量、确定、识别、确认或验证细胞群治疗潜力的细胞效力检测方法。细胞效力测定可对各种类型的细胞进行，包括干细胞或祖细胞，例如造血干细胞或祖细胞。细胞效力检测也可对经过一种或多种药剂处理以提高治疗潜力的干细胞或祖细胞进行。具有治疗潜能的造血细胞可用于下游临床应用，以增加体内的移植、重组、归巢和增殖。